A5105928815- Estrogen and related hormone effects
- Menopause: Health Impacts and Treatments
- Reproductive Health and Contraception
- Endometriosis Research and Treatment
- Ovarian function and disorders
- Uterine Myomas and Treatments
- Phytoestrogen effects and research
- Reproductive System and Pregnancy
- Endometrial and Cervical Cancer Treatments
- Hormonal and reproductive studies
- Ectopic Pregnancy Diagnosis and Management
- Gynecological conditions and treatments
- Pregnancy and Medication Impact
- Sexual function and dysfunction studies
- Growth Hormone and Insulin-like Growth Factors
- Reproductive tract infections research
- Maternal and fetal healthcare
- Pelvic floor disorders treatments
- Angiogenesis and VEGF in Cancer
- Pregnancy-related medical research
- Urticaria and Related Conditions
- Maternal Mental Health During Pregnancy and Postpartum
- Reproductive Biology and Fertility
- Pituitary Gland Disorders and Treatments
- Cancer Risks and Factors
Eastern Virginia Medical School
2015-2024
Jones Institute
2011-2024
Columbia University
2010-2024
Clinical Research Management
2010-2024
University of California, San Francisco
2018-2024
Corteva (United States)
2024
American Institute for Economic Research
2021-2024
Eunice Kennedy Shriver National Institute of Child Health and Human Development
2010-2024
University of California, San Diego
2018-2024
University of California, Berkeley
2024
Endometriosis is a chronic, estrogen-dependent condition that causes dysmenorrhea and pelvic pain. Elagolix, an oral, nonpeptide, gonadotropin-releasing hormone (GnRH) antagonist, produced partial to nearly full estrogen suppression in previous studies.We performed two similar, double-blind, randomized, 6-month phase 3 trials (Elaris I II [EM-I EM-II]) evaluate the effects of doses elagolix - 150 mg once daily (lower-dose group) 200 twice (higher-dose as compared with placebo women...
Ten years after the first results from Women's Health Initiative (WHI) trial were published, it seems that atmosphere around issue of menopausal hormone therapy (MHT) is increasingly ev...
The aim of this study is to confirm the local beneficial effects intravaginal dehydroepiandrosterone (DHEA, Prasterone) on moderate severe dyspareunia or pain at sexual activity, most frequent symptom vulvovaginal atrophy due menopause genitourinary syndrome (GSM).In a prospective, randomized, double-blind, and placebo-controlled phase III clinical trial, effect daily 0.50% DHEA (6.5 mg) (Prasterone, EndoCeutics) was examined four coprimary objectives, namely percentage parabasal cells,...
Uterine fibroids are hormone-responsive neoplasms that associated with heavy menstrual bleeding. Elagolix, an oral gonadotropin-releasing hormone antagonist resulting in rapid, reversible suppression of ovarian sex hormones, may reduce fibroid-associated
In Brief OBJECTIVE: Compare the efficacy and adverse effects of CDB-2914, a new progesterone receptor modulator, to levonorgestrel for emergency contraception. METHODS: We performed randomized, double-blinded noninferiority trial, enrolling healthy women seeking contraception within 72 hours unprotected intercourse. Participants were randomly assigned receive single dose 50 mg plus placebo 12 later or two doses 0.75 taken apart. Follow-up was scheduled 5 7 days after expected onset next...
Prospective evaluation of 155 couples with two or more consecutive pregnancy losses disclosed uterine morphologic abnormalities in 27%, chromosomal 21 individuals (7.7%, 15.4% the couples), and at least one abnormal diagnostic test suggestive a cause for recurrent 106 (68%). A positive antinuclear antibody was found 7.5% women, whereas expected rate population this age is less than 2%. Cervical cultures Ureaplasma urealyticum (T-strain mycoplasma) were 48% 28% these women had genetic...
The objective of this study was to provide evidence that the transformation DHEA into both androgens and/or estrogens locally in cells three layers vagina (epithelium, lamina propria, and muscularis) would have effects greater impact, including on sexual function, than only superficial epithelial as achieved with estrogens.This prospective, randomized, double-blind, placebo-controlled phase III clinical trial has evaluated effect daily local intravaginal application Prasterone...
In Brief Objective: Because the secretion of dehydroepiandrosterone (DHEA), exclusive source sex steroids in postmenopausal women, is already decreased by 60% and continues to decline at time menopause, objective this study was examine effect intravaginal DHEA on symptoms signs vaginal atrophy. Methods: This prospective, randomized, double-blind placebo-controlled phase III clinical trial studied Prasterone (DHEA) applied locally vagina atrophy 216 women. Results: All three doses (0.25%,...
To evaluate the efficacy of ultra-low-dose 10-microgram 17beta-estradiol (E2) vaginal tablets for treatment atrophy.Postmenopausal women (N=309) were randomly assigned to E2 or placebo 52 weeks in a multicenter, double-blind study. Primary endpoints included change from baseline week 12 cytology, pH, and most bothersome urogenital symptoms score. Grading health was secondary assessment. Safety assessments endometrial biopsy, physical gynecologic examinations, recording adverse events.At 12,...
This phase 3 study evaluated the endometrial safety of bazedoxifene (BZA)/conjugated estrogens (CE) and bone mineral density (BMD) effects vs BZA alone, hormone therapy, placebo (PBO). The Selective estrogens, Menopause, And Response to Therapy (SMART)-5 trial was a multicenter, randomized, double-blind, PBO- active-controlled in postmenopausal women with an intact uterus (N = 1843; aged 40–65 years) seeking treatment for menopausal symptoms. Subjects received daily oral 20 mg/CE 0.45 or...
The objective of this consensus document is to broaden the perspective on clinical management genitourinary syndrome menopause include androgens.A modified Delphi method was used reach among 14 international panelists representing multiple disciplines and societies.Menopause-related symptoms affect over 50% midlife older women. These have a marked impact sexual functioning, daily activities, emotional well-being, body image, interpersonal relations. Tissues in system are both androgen...
To evaluate the efficacy and safety of elagolix, an oral, nonpeptide gonadotropin-releasing hormone antagonist, over 12 months in women with endometriosis-associated pain.Elaris Endometriosis (EM)-III -IV were extension studies that evaluated additional 6 treatment after two 6-month, double-blind, placebo-controlled phase 3 trials (12 continuous months) elagolix doses (150 mg once daily 200 twice daily). Coprimary endpoints proportion responders (clinically meaningful pain reduction stable...
Abstract Objective: The aim of this study is to confirm the local beneficial effects intravaginal dehydroepiandrosterone (DHEA, Prasterone) on moderate severe dyspareunia or pain at sexual activity, most frequent symptom vulvovaginal atrophy due menopause genitourinary syndrome (GSM). Methods: In a prospective, randomized, double-blind, and placebo-controlled phase III clinical trial, effect daily 0.50% DHEA (6.5 mg) (Prasterone, EndoCeutics) was examined four coprimary objectives, namely...
This study aims to confirm the local effects of intravaginal prasterone on moderate severe dyspareunia, a symptom vulvovaginal atrophy (VVA) associated with menopause.In prospective, randomized, double-blind, placebo-controlled phase III clinical trial, we examined daily (6.5 mg) four co-primary objectives, namely, percentage vaginal parabasal cells, superficial pH, and dyspareunia identified by women as most bothersome VVA symptom.After administration for 12 weeks, cells decreased 45.8%...